Core Insights - TNX-4800 is a long-acting monoclonal antibody in development as a single-dose prophylactic for Lyme disease, demonstrating safety and pharmacokinetics supportive of approximately four months of protection [1][2][3] Phase 1 Study Results - The Phase 1 study evaluated the safety and tolerability of TNX-4800 in 44 healthy subjects aged 19-65, with 41 completing the study [4][10] - No significant safety signals were observed, with most adverse events being mild or moderate [5][12] - Peak serum concentration increased by approximately 25-fold for a 20-times increase in dose, with serum TNX-4800 measurable at two days and remaining quantifiable for over 200 days in 80% of subjects at the lowest dose [5][12] Mechanism and Advantages - TNX-4800 targets the outer surface protein A (OspA) of Borrelia burgdorferi, which causes 99.9% of Lyme disease cases in the U.S. [2][9] - The antibody provides passive immunity by directly supplying neutralizing antibodies, bypassing the need for a vaccine to induce the immune system [4][9] - Unlike existing vaccines that require complex immunization schedules and take over six months to provide protection, TNX-4800 offers immunity within two days with a single subcutaneous dose [3][9] Future Study Plans - The company plans to initiate a randomized, double-blind, placebo-controlled adaptive Phase 2 field study in the first half of 2027, pending FDA clearance [1][6] - The primary endpoint will be the prevention of Lyme disease at four months, with a key secondary endpoint at six months [6][11] Product Development and Background - TNX-4800 was in-licensed from UMass Chan Medical School in 2025 and is designed to maintain protective antibody levels for approximately four months [2][9] - The company expects to have GMP investigational product available for clinical testing in early 2027 [7]

Core Insights - Tonix Pharmaceuticals announced the presentation of Phase 1 data on TNX-4800, a long-acting human monoclonal antibody for the seasonal prevention of Lyme disease, at the World Vaccine Congress Washington 2026 [1][3] Group 1: TNX-4800 Overview - TNX-4800 targets the outer surface protein A (OspA) of Borrelia burgdorferi, the bacterium responsible for Lyme disease, and has shown 95% effectiveness in preventing infection in animal studies [4][6] - The antibody is designed to provide immunity within two days of administration and maintain protective antibody levels throughout the tick season, offering a pre-exposure prophylaxis without relying on the recipient's immune system [4][6] - The company expects to have GMP investigational product available for clinical testing in early 2027, with a field study anticipated to begin enrollment in the first half of 2027 [5] Group 2: TNX-801 Overview - TNX-801 is a live attenuated horsepox virus vaccine candidate aimed at preventing smallpox and mpox, expected to enter Phase 1 studies in 2027 pending FDA clearance [8] Group 3: Phase 1 Study Details - The Phase 1 study of TNX-4800 involved 44 subjects, with 41 completing the study, assessing safety, tolerability, pharmacokinetics, and immunogenicity [6] - Drug exposure increased approximately 25 times for a 20 times increase in dose, with serum TNX-4800 measurable within 24 hours and remaining quantifiable for over 200 days in 80% of volunteers at the lowest dose [6] - The mean half-life of TNX-4800 ranged from 62-69 days, with most adverse events being mild or moderate, indicating that TNX-4800 is generally safe and well tolerated [6] Group 4: Lyme Disease Context - Lyme disease is the most common vector-borne infection in the U.S., caused by Borrelia burgdorferi, with increasing incidence due to climate changes affecting tick habitats [7] - Typical symptoms include fever, headache, fatigue, and a characteristic skin rash, with untreated infections potentially spreading to joints, heart, and nervous system [7]

Company Overview - Tonix Pharmaceuticals Holding Corp. is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments addressing high unmet medical needs [2] - The company’s marketed products include TONMYA, the first new treatment for fibromyalgia in over 15 years, and acute migraine products Zembrace Symtouch and Tosymra [2] - Tonix is advancing a pipeline that includes investigational drugs for major depressive disorder, acute stress disorder, Prader-Willi syndrome, Lyme disease prophylaxis, and kidney transplant rejection [2] Upcoming Presentation - Seth Lederman, MD, the CEO of Tonix, will present at BIO-Europe Spring 2026 on March 24, 2026, from 1:30 to 1:45 p.m. WET in Lisbon, Portugal [1][2] - The presentation will take place in Presentation Theatre A [2] Product Development - TONMYA is currently being evaluated in Phase 2 clinical trials for its potential in treating major depressive disorder and acute stress disorder [2] - TNX-2900 is Phase 2 ready for treating Prader-Willi syndrome, a rare disease [2] - The immunology pipeline includes monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor aimed at preventing kidney transplant rejection [2]

Core Insights - Tonix Pharmaceuticals Holding Corp. announced presentations on its preclinical immuno-oncology portfolio at the AACR Annual Meeting 2026, scheduled for April 17–22, 2026, in San Diego, California [1] Oral Presentation Details - The oral presentation titled "TFF2 deficiency amplifies IL-1β-driven inflammation and promotes aging-associated gastric tumor progression" will take place on April 21, 2026, from 2:30–4:30 p.m. PT [2] - Presenters include Shuang Li, MD, PhD, and Timothy C. Wang, MD, with Tonix co-authors Seth Lederman, MD, and Bruce L. Daugherty, PhD, MBA [2] Poster Presentation Details - The first poster presentation titled "In vitro characterization of fully human antagonistic anti-BTLA monoclonal antibodies" is scheduled for April 21, 2026, from 2:00-5:00 p.m. PT [3] - The second poster presentation titled "Pharmacokinetics of TNX-1700 in non-human primates and human FcRn/serum albumin transgenic mice" will occur on April 22, 2026, from 9:00 a.m.–12:00 p.m. PT [3] - Both presentations will be led by Bruce Daugherty, PhD, MBA [3] About TNX-1700 - TNX-1700 is a fusion protein of TFF2 and albumin, currently in preclinical development for treating gastric and colorectal cancer in combination with PD-1 blockade [4] - The drug is in the pre-Investigational New Drug (IND) stages of development and was in-licensed from Columbia University [4] Company Overview - Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on CNS and immunology treatments for high unmet medical needs [5] - The company’s marketed products include TONMYA for fibromyalgia, Zembrace® Symtouch® for acute migraines, and Tosymra® [5] - Tonix is also investigating TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder, and has a pipeline including TNX-2900 for Prader-Willi syndrome and monoclonal antibodies for Lyme disease prophylaxis and kidney transplant rejection [5]

Core Viewpoint - Tonix Pharmaceuticals has launched TONMYA, the first FDA-approved treatment for fibromyalgia in over 15 years, demonstrating rapid pain relief and a favorable benefit-risk profile in clinical studies [1][2]. Group 1: Product Overview - TONMYA (cyclobenzaprine HCl sublingual tablets) was approved by the FDA on August 15, 2025, for the treatment of fibromyalgia in adults [9]. - The formulation allows for rapid transmucosal absorption and reduces the production of a long half-life active metabolite, norcyclobenzaprine, due to bypassing first-pass hepatic metabolism [9]. - TONMYA is also being investigated for other conditions, including acute stress reaction, acute stress disorder, and major depressive disorder [9]. Group 2: Clinical Study Results - In the RESILIENT trial, TONMYA showed significant pain reduction as early as Day 2, with a statistically significant change in weekly average daily numeric rating scale (NRS) pain scores (p<0.001) [3]. - The primary endpoint was met with a least-squares mean treatment difference of -0.65, and all key secondary endpoints were statistically significant in favor of TONMYA [3]. - A pooled analysis of the RELIEF and RESILIENT studies indicated that the number needed to treat (NNT) for a clinically meaningful ≥30% pain reduction was 7, while the number needed to harm (NNH) for discontinuation due to adverse events was 26, resulting in a likelihood to be helped or harmed (LHH) of 3.7 [5]. Group 3: Safety and Tolerability - TONMYA was generally well tolerated, with a discontinuation rate due to adverse events of 6.1% compared to 3.5% for placebo [4]. - The most common treatment-emergent adverse events included oral cavity reactions, such as oral hypoesthesia (23.8%) and abnormal product taste (11.7%), which were typically mild and transient [4][6]. - Safety data were consistent with the known profile of TONMYA, with no new or unexpected safety signals reported [6]. Group 4: Market Context - Approximately 10 million adults in the U.S. suffer from fibromyalgia, with a significant unmet medical need for effective treatments [2][8]. - Physicians and patients have expressed dissatisfaction with currently marketed products, highlighting the potential market opportunity for TONMYA [8].

Core Viewpoint - Tonix Pharmaceuticals Inc. has recently uplisted to the Nasdaq Global Select Market, which may enhance its visibility among institutional investors and improve liquidity despite a bearish trend in the broader market [1][2]. Group 1: Uplisting Details - Trading on the Nasdaq Global Select Market commenced on March 3, 2026, under the ticker symbol "TNXP" [2]. - The CEO, Seth Lederman, highlighted the uplisting as a significant milestone, reflecting the company's commitment to growth and shareholder value [2]. Group 2: Market Implications - The uplisting may indicate that Tonix has achieved financial and operational growth, potentially leading to increased trading volumes and better access to institutional investors [3]. - The company is focused on developing treatments for central nervous system and immunology conditions, with its flagship product, TONMYA, being the first new treatment for fibromyalgia in over 15 years [3]. Group 3: Stock Performance - Tonix Pharmaceuticals is currently trading 9.8% below its 20-day simple moving average (SMA) and 4.1% below its 100-day SMA, indicating a bearish trend [4]. - Over the past 12 months, shares have significantly decreased and are closer to their 52-week lows than highs, reflecting ongoing challenges in stock performance [4]. - The RSI is at 44.45, indicating neutral territory, while the MACD is at 0.15, below its signal line at 0.22, suggesting bearish pressure on the stock [5]. Group 4: Price Action - During premarket trading, Tonix Pharmaceuticals shares were down 2% at $13.70 [6]. - Key resistance level is identified at $15.00, while key support is at $12.50 [6].

Core Viewpoint - Tonix Pharmaceuticals Holding Corp. is actively engaging with investors through presentations and meetings at various conferences in January 2026, showcasing its innovative pipeline and marketed products in the biotechnology sector [1][2][3]. Company Overview - Tonix Pharmaceuticals is a fully integrated biotechnology company with marketed products and a robust pipeline of development candidates [4]. - The company markets FDA-approved TONMYA™, a first-in-class, non-opioid analgesic for fibromyalgia, which is the first new prescription medicine approved for this condition in over 15 years [4]. - Tonix also offers treatments for acute migraine, including Zembrace® SymTouch® and Tosymra® [4]. Product Pipeline - Tonix's development portfolio focuses on central nervous system (CNS) disorders, immunology, immuno-oncology, rare diseases, and infectious diseases [4]. - Key candidates include: - TNX-102 SL for acute stress reaction and major depressive disorder [4]. - TNX-1500, a Phase 2-ready monoclonal antibody for organ transplant rejection and autoimmune diseases [4]. - TNX-2900 for Prader-Willi syndrome, expected to start a pivotal Phase 2 study in 2026 [4]. - TNX-801, a vaccine for mpox and smallpox, and TNX-4800, a monoclonal antibody for Lyme disease prevention [4]. - TNX-4200, a broad-spectrum antiviral agent with a contract for up to $34 million from the U.S. Department of Defense [4]. Upcoming Conferences - Tonix's management will present at the Sachs Associates 9th Annual Neuroscience Innovation Forum on January 11, 2026, and at the Biotech Showcase 2026 on January 13, 2026 [2][3]. - The presentations will be led by Seth Lederman, M.D., the President and CEO of Tonix Pharmaceuticals [2][3]. Investor Relations - Investors interested in meetings with the company's management during the conferences can contact the provided email [4]. - Additional information about Tonix and its products can be found on the company's website [6].

Core Insights - Tonix Pharmaceuticals is developing TNX-4800, a long-acting human monoclonal antibody targeting Borrelia burgdorferi, the causative agent of Lyme disease, with plans for clinical trials to begin in early 2027 [1][2][3] Group 1: Product Development - TNX-4800 is designed for annual seasonal use, administered subcutaneously in the spring to provide protection against Lyme disease throughout the tick season [1][3] - The company plans to meet with the FDA in 2026 to discuss Phase 2/3 development options, including a controlled human infection model (CHIM) study [2] - TNX-4800 has shown 95% effectiveness in preventing infection in non-human primates after exposure to infected ticks [3] Group 2: Market Potential - Approximately 70 million people in the U.S. living in Lyme disease-endemic areas could benefit from TNX-4800 as a pre-exposure prophylactic [1] - There are currently no FDA-approved vaccines or prophylactics available for Lyme disease in the U.S., highlighting a significant market opportunity for TNX-4800 [1][2] Group 3: Safety and Efficacy - TNX-4800 demonstrated rapid systemic absorption, with serum concentrations remaining quantifiable for over 200 days in 80% of volunteers at the lowest dose [4][5] - The mean half-life of TNX-4800 ranged from 62 to 69 days across different dosage groups, indicating prolonged efficacy [4] - Most adverse events reported were mild or moderate, and TNX-4800 was generally well tolerated [5] Group 4: Lyme Disease Overview - Lyme disease is the most common vector-borne infection in the U.S., with increasing incidence, particularly in the Northeast, mid-Atlantic, and upper-Midwest regions [6] - Typical symptoms include fever, headache, fatigue, and a characteristic skin rash, with untreated cases potentially leading to severe complications [6]

Core Insights - Tonix Pharmaceuticals has licensed exclusive worldwide rights to TNX-4900, a selective Sigma-1 receptor antagonist, which has shown analgesic activity in various neuropathic pain models [1][2] - The company aims to advance TNX-4900 through further pharmacokinetic, formulation, and safety studies to support IND-enabling development [4] Company Overview - Tonix Pharmaceuticals is a fully-integrated biotechnology company with marketed products and a pipeline focused on central nervous system disorders, immunology, immuno-oncology, rare diseases, and infectious diseases [5] - The company markets FDA-approved TONMYA, a non-opioid analgesic for fibromyalgia, and has additional treatments for acute migraine [5] Product Development - TNX-4900 was developed using computer-aided and AI-driven approaches, demonstrating robust analgesic efficacy and a favorable safety profile in preclinical models [2][4] - The compound binds to the human Sigma-1 receptor with a nanomolar affinity (Ki = 7.5 nM) and shows over 100-fold selectivity over the Sigma-2 receptor, with an oral bioavailability of approximately 28% [2] Research and Innovation - Foundational research into TNX-4900 represents a significant step towards developing non-opioid solutions for chronic pain, addressing the need for safer pain management options [3] - The compound has produced significant and durable reductions in pain behaviors in preclinical models without evidence of tolerance or motor impairment [4]

Core Insights - Tonix Pharmaceuticals has received FDA clearance for the IND application of TNX-102 SL, a sublingual tablet formulation for treating major depressive disorder (MDD) in adults, with plans to initiate a pivotal Phase 2 HORIZON study in mid-2026 [1][2][4] Company Overview - Tonix Pharmaceuticals is a fully-integrated biotechnology company with a focus on central nervous system disorders, immunology, and infectious diseases, and markets FDA-approved products including TONMYA for fibromyalgia [7][8] - The company is developing TNX-102 SL not only for MDD but also for other indications such as Long COVID, PTSD, and agitation in Alzheimer's disease [5][7] Clinical Development - The Phase 2 HORIZON study will be a 6-week, randomized, double-blind, placebo-controlled trial involving approximately 360 patients across 30 U.S. sites, targeting adults aged 18 and older experiencing moderate to severe MDD [2][4] - The primary endpoint of the study is the change in MADRS total score from baseline at Week 6, with secondary endpoints including global impression scores and measures of sleep disturbance [2][4] Mechanism of Action - TNX-102 SL is designed to address disturbed sleep associated with depression, utilizing a novel mechanism of action that differentiates it from traditional antidepressants [3][5] - The formulation allows for rapid absorption and minimizes the production of the active metabolite, potentially reducing side effects commonly associated with traditional antidepressants [5][6] Market Need - Over 21 million adults in the U.S. experience a major depressive episode annually, highlighting the urgent need for effective and well-tolerated treatment options [4][5] - Many existing antidepressants are not adequately effective for all patients, and side effects often lead to discontinuation of treatment, underscoring the demand for innovative therapies [4][5]